Interventional and Structural Heart Cardiology, Interventional Cardiology Heart Institute, Medanta-The Medicity, Gurgaon, Haryana, India.
Department of Cardiology, Meenakshi Mission Hospital and Research Centre, Madurai, Tamil Nadu, India.
Indian Heart J. 2023 Jul-Aug;75(4):236-242. doi: 10.1016/j.ihj.2023.05.008. Epub 2023 May 26.
Optical coherence tomography (OCT) is reported to be a feasible and safe imaging modality for the guidance of percutaneous coronary intervention (PCI) of complex lesions.
This multicenter, prospective registry assessed the minimum stent area (MSA) achieved under OCT guidance. A performance goal of 24% improvement in MSA over and above the recommendation set by the European Association of Percutaneous Cardiovascular Interventions Consensus 2018 (4.5 mm MSA for non-left main and 3.5 mm for small vessels). The incidence of contrast-induced nephropathy was also assessed. Core lab analysis was conducted.
Five hundred patients (average age: 59.4 ± 10.1 years; 83% males) with unstable angina (36.8%), NSTEMI (26.4%), and STEMI (22%) were enrolled. The primary endpoint was achieved in 93% of lesions with stent diameter ≥2.75 mm (average MSA: 6.44 mm) and 87% of lesions with stent diameter ≤2.5 mm (average MSA: 4.56 mm). The average MSA (with expansion ≥80% cutoff) was 6.63 mm and 4.74 mm with a stent diameter ≥2.75 mm and ≤2.5 mm, respectively. According to the core lab analysis, the average MSA achieved with a stent diameter ≥2.75 mm and ≤2.5 mm was 6.23 mm and 3.95 mm, respectively (with expansion ≥80% cutoff). Clinically significant serum creatinine was noted in two patients (0.45%). Major adverse cardiac events at 1 year were noted in 1.2% (n = 6) of the patients; all were cardiac deaths.
PCI under OCT guidance improves procedural and long-term clinical outcomes in patients with complex lesions not just in a controlled trial environment but also in routine clinical practice.
光学相干断层扫描(OCT)被报道为一种可行且安全的成像方式,可用于指导复杂病变的经皮冠状动脉介入治疗(PCI)。
这项多中心前瞻性注册研究评估了 OCT 指导下实现的最小支架面积(MSA)。以 2018 年欧洲经皮心血管介入协会共识建议(非左主干病变为 4.5mm2,小血管病变为 3.5mm2)为基础,设定了 24%的 MSA 改善作为性能目标。还评估了对比剂肾病的发生率。进行了核心实验室分析。
500 例患者(平均年龄:59.4±10.1 岁;83%为男性)被纳入研究,其中不稳定型心绞痛(36.8%)、非 ST 段抬高型心肌梗死(NSTEMI)(26.4%)和 ST 段抬高型心肌梗死(STEMI)(22%)。主要终点在支架直径≥2.75mm 的 93%病变(平均 MSA:6.44mm)和支架直径≤2.5mm 的 87%病变(平均 MSA:4.56mm)中实现。平均 MSA(扩张≥80%的截断值)分别为 6.63mm 和 4.74mm,支架直径分别为≥2.75mm 和≤2.5mm。根据核心实验室分析,支架直径≥2.75mm 和≤2.5mm 时平均 MSA 分别为 6.23mm 和 3.95mm(扩张≥80%的截断值)。有两名患者(0.45%)出现临床意义的血清肌酐升高。1 年内发生 1.2%(n=6)的主要不良心脏事件,均为心脏死亡。
OCT 指导下的 PCI 不仅在临床试验环境中,而且在常规临床实践中,均可改善复杂病变患者的手术和长期临床结局。